These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://sauljyye833005.blogpostie.com/60284033/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide